RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study
“RMC-6236 is the first targeted investigational drug designed to directly inhibit all major forms of oncogenic RAS, the major drivers of PDAC. RMC-6236 has shown compelling anti-tumor activity and a favorable safety profile in a broad population of patients with previously treated PDAC, and has potential to become an important new treatment option. Extensive efforts are ongoing toward launching RASolute 302, a global, randomized Phase 3 clinical trial comparing RMC-6236 to chemotherapy as 2L treatment of patients with metastatic PDAC.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo